propofol

propofol
Name	Propofol
Tradename	Diprivan, others
Routes of administration	Intravenous
Protein bound	~97–99%
Metabolism	Hepatic conjugation
Onset	30–60 seconds
Duration of action	5–10 minutes (single bolus)
Elimination half-life	1–3 hours
Excretion	Renal

propofol is a short-acting intravenous sedative-hypnotic agent used for induction and maintenance of anesthesia, sedation for procedures, and intensive care unit sedation. It produces rapid loss of consciousness, amnesia, and dose-dependent respiratory and cardiovascular depression. Propofol is central to contemporary anesthesia practice across perioperative, emergency, and critical care settings.

Medical uses

Propofol is used for induction of general anesthesia for procedures in settings from outpatient clinics to tertiary centers such as Mayo Clinic, Johns Hopkins Hospital, and Cleveland Clinic. It is commonly employed for maintenance of anesthesia during surgeries referenced in literature from institutions like Massachusetts General Hospital and Charité – Universitätsmedizin Berlin. In the endoscopy suites of facilities including Mount Sinai Hospital and Royal Free Hospital, propofol provides sedation for procedures such as colonoscopy and upper endoscopy, where alternatives like agents used at Guy's Hospital and St Thomas' Hospital have been compared. In intensive care units at hospitals such as Barnes-Jewish Hospital and UCLA Medical Center, propofol is favored for mechanical ventilation sedation, though long-term use considerations have been influenced by reports from agencies including the Food and Drug Administration and professional societies such as the American Society of Anesthesiologists.

Propofol is also used for procedural sedation in emergency departments exemplified by practice at Massachusetts General Hospital and Royal Infirmary of Edinburgh, and for monitored anesthesia care in settings tied to centers such as Karolinska University Hospital and Guy's and St Thomas' NHS Foundation Trust. Off-label uses and research into neuroprotective hypotheses have involved collaborations with universities like Harvard University, University of Oxford, and Stanford University.

Pharmacology

Propofol acts primarily as a positive allosteric modulator of the gamma-aminobutyric acid type A receptor, a mechanism studied in laboratories affiliated with NIH and universities such as Yale University and University College London. It enhances inhibitory neurotransmission in brain regions including structures examined in work at Beth Israel Deaconess Medical Center and Karolinska Institutet, producing rapid sedation and hypnosis. Its pharmacokinetics—rapid distribution and clearance—were characterized in studies by groups at University of California, San Francisco and Imperial College London.

Metabolism occurs mainly by hepatic conjugation with contributions from extrahepatic pathways described in research from University of Toronto and Monash University. Propofol’s lipophilic formulation and emulsion vehicle were developed and patented in collaborations involving entities such as AstraZeneca and investigated in clinical trials at centers like University of Pennsylvania. Drug interactions with agents used at institutions such as Cleveland Clinic—including benzodiazepines, opioids, and volatile anesthetics—affect dosing and recovery profiles and have been addressed in guidelines from organizations like the European Society of Anaesthesiology.

Administration and dosing

Propofol is administered intravenously in bolus doses for induction and as continuous infusion for maintenance or sedation in settings ranging from ambulatory surgical centers like Surgery Center of Oklahoma to tertiary referral hospitals such as Brigham and Women's Hospital. Induction dosing for adults is typically titrated based on clinical protocols used at centers including Johns Hopkins Hospital and Mayo Clinic; pediatric dosing follows studies from children's hospitals such as Boston Children’s Hospital and Great Ormond Street Hospital. Target-controlled infusion systems developed in research units at University of Edinburgh and Erasmus MC allow calculated plasma or effect-site targeting.

Protocols for special populations have been informed by trials at institutions like Mount Sinai Hospital and Royal Children's Hospital, addressing elderly sensitivity documented by teams at Addenbrooke's Hospital and renal or hepatic impairment guidance from groups at Karolinska University Hospital. Peri-procedural monitoring standards employing technology produced by companies linked to Royal Brompton Hospital and Guy's and St Thomas' Hospital emphasize airway management and cardiovascular monitoring.

Adverse effects and complications

Common adverse effects include hypotension and respiratory depression observed in cohorts studied at Massachusetts General Hospital and Mayo Clinic. Pain on injection has been mitigated by coadministration strategies investigated at University of Miami and University of Michigan. Rare but serious complications include propofol infusion syndrome, characterized by metabolic acidosis, rhabdomyolysis, and cardiac failure, initially reported in case series connected to pediatric intensive care units such as Great Ormond Street Hospital and later reviewed by panels at Children's Hospital of Philadelphia and regulatory bodies like the European Medicines Agency.

Allergic reactions related to egg or soy components in formulations were explored by researchers at Cleveland Clinic and Royal Free Hospital. Neuroexcitation and emergence phenomena have been described in case reports from centers like Toronto General Hospital and Guy's Hospital. Drug diversion and misuse concerns, highlighted in investigations involving institutions such as Los Angeles County+USC Medical Center and legal proceedings in jurisdictions including New York City, led to tightened controls and professional policy statements from organizations including the American Medical Association.

Contraindications and precautions

Absolute contraindications include known hypersensitivity to components of the emulsion, a consideration in allergy clinics at institutions such as Mayo Clinic and Johns Hopkins Hospital. Caution is advised in patients with limited cardiopulmonary reserve—guidance reflecting practice at Royal Brompton Hospital and St Thomas' Hospital—and in settings with limited airway support like smaller community hospitals exemplified by St. Mary's Hospital networks. Pediatric and neonatal use requires specialized protocols developed at Great Ormond Street Hospital and Boston Children's Hospital. Perioperative care pathways incorporating propofol have been standardized by groups at University College London Hospitals and Guy's and St Thomas' NHS Foundation Trust to mitigate risks.

History and development

Propofol was first synthesized and characterized in the 1970s, with early clinical development conducted through collaborations involving research laboratories and pharmaceutical companies such as ICI Pharmaceuticals (later AstraZeneca) and clinical testing at hospitals including St Thomas' Hospital and Royal Postgraduate Medical School. Key clinical introductions and approval processes involved regulatory authorities like the Food and Drug Administration and Medicines and Healthcare products Regulatory Agency. Historical accounts of its adoption in anesthesia practice reference influential departments at Massachusetts General Hospital, Guy's Hospital, and Charité – Universitätsmedizin Berlin, and biographical notes on investigators appear in archives at University of Liverpool and University of Birmingham.

Category:Anesthetics